Innate Pharma (XPAR:IPH) Other Stockholders Equity : €0.00 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Other Stockholders Equity?

Innate Pharma's Other Stockholders Equity for the quarter that ended in Dec. 2023 was €0.00 Mil.

Innate Pharma's quarterly Other Stockholders Equity declined from Dec. 2022 (€-0.00 Mil) to Jun. 2023 (€-0.00 Mil) but then increased from Jun. 2023 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Innate Pharma's annual Other Stockholders Equity increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€-0.00 Mil) and increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Innate Pharma Other Stockholders Equity Historical Data

The historical data trend for Innate Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Other Stockholders Equity Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Innate Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Innate Pharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines